HomeAI · summaries
Storia in 11 fonti
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials - AstraZeneca (NYSE:AZN)
AstraZeneca advances oral GLP-1 elecoglipron to Phase 3 following strong weight loss & diabetes data at ADA 2026. Get the trial details.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
Novel Once-Daily Pill Delivers Positive Blood Glucose and Weight Reduction Results
- ·
statnews.com
AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
